XXII 22nd Century Group Inc.

22nd Century Group (Nasdaq: XXII) Announces Management Updates and Departure of Chief Operating Officer

22nd Century Group (Nasdaq: XXII) Announces Management Updates and Departure of Chief Operating Officer

BUFFALO, N.Y., Sept. 07, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced changes in its management team as the Company accelerates growth in its reduced nicotine content tobacco business. The Company announced that Michael Zercher, President and Chief Operating Officer, will depart the Company effective September 30, 2022. John Miller, who leads 22nd Century’s tobacco business team, will assume the tobacco-related duties of the Chief Operating Officer’s role, while Chief Executive Officer James A. Mish will assume the title of Corporate President.

“With exceptionally successful VLN® pilot results in hand, 22nd Century is expanding sales and planning rollouts in strategic regions across the United States,” said James A. Mish, chief executive officer of 22nd Century. “In order to coordinate all of the critical elements of this expansion plus additional planned market launches, John Miller, who already leads our tobacco product, marketing and partnership efforts, will assume full operational responsibility for the tobacco product lines, bringing to bear his more than 30 years of industry experience to direct a fully integrated national VLN® sales strategy.”

On behalf of the Board of Directors and the entire Company, I thank Mike for his work at 22nd Century Group, including his important role in helping bring VLN® through the regulatory process to secure the first and only FDA Modified Risk Tobacco Product marketing order ever granted to a combustible cigarette. Mike has also been instrumental in developing our initial VLN® industry partnerships and successful Chicagoland pilot program,” said Mish. “As a result, 22nd Century represents a completely new type of tobacco business focused on disrupting the industry and, most importantly, helping adult smokers to smoke less. We thank Mike for the incredible success he has helped the Company achieve and wish him well in his future endeavors.”

About 22nd Century Group, Inc.

22nd Century Group, Inc. (Nasdaq: ) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the  to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at , on , on , and on .

Learn more about VLN® at .

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 1, 2022, and in the Company’s Quarterly Report filed on August 9, 2022. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact

Mei Kuo

22nd Century Group, Inc.

Director, Communications & Investor Relations

Darrow Associates Investor Relations

Matt Kreps

T: 214-597-8200



EN
07/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 22nd Century Group Inc.

 PRESS RELEASE

22nd Century Group’s GVB Biopharma Opens New Central Distribution Faci...

22nd Century Group’s GVB Biopharma Opens New Central Distribution Facility in The Netherlands New distribution facility supports rapidly growing demand for hemp/cannabis products BUFFALO, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- , a 22nd Century Group company (Nasdaq: ), today announced that it has opened a new, strategically-located distribution facility in the Netherlands to support its growing business in Europe, the Middle East, and Africa (EMEA). The new distribution facility will increase existing and new customer access to GVB’s quality hemp/cannabis products, speed up transaction...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon...

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon in Las Vegas BUFFALO, N.Y., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company’s GVB Biopharma business will attend and be an exhibitor at MJBizCon in Las Vegas on November 16 to 18, 2022. “We’re excited to be exhibiting at MJBizCon for the fourth year, and this time with the combined GVB and 22nd Century team...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) to Participate in November 2022 Inve...

22nd Century Group (Nasdaq: XXII) to Participate in November 2022 Investor Conferences BUFFALO, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company will be participating in the following investor conferences: On Tuesday, November 15, 2022, the Company will host one-on-one meetings at the Roth 2nd Annual AgTech Answers Event.On Thursday, November 17, 2022, the Company will ho...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Fina...

22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the Third Quarter 2022 Accelerating VLN® Sales in Colorado and Illinois, Launching in Four Corners States to Capture Market Share and VolumeGVB Biopharma Acquisition Growing Revenue on Increased VolumesThird Quarter Net Sales $19.4 Million, Up 148% from the Third Quarter 2021Strong Balance Sheet to Support Strategic Initiatives Including Accelerated VLN® Expansion BUFFALO, N.Y., Nov. 08, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicate...

 PRESS RELEASE

New Study Again Shows 22nd Century’s Reduced Nicotine Content Cigarett...

New Study Again Shows 22nd Century’s Reduced Nicotine Content Cigarettes Reduce Cigarette Consumption and Increase Smoking Cessation Reduced nicotine cigarettes increase cessation, decrease consumption, decrease dependence, and reduce toxicantsStudy dispels common misconception that reduced nicotine cigarettes worsen general health and mental health problems BUFFALO, N.Y., Nov. 07, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch